Cyclo Therapeutics Net Worth
Cyclo Therapeutics Net Worth Breakdown | CYTHW |
Cyclo Therapeutics Net Worth Analysis
Cyclo Therapeutics' net worth analysis, or its valuation, is the process of determining the total value of the company. This involves assessing a range of factors, including Cyclo Therapeutics' financial performance, assets, liabilities, and potential for growth. The ultimate goal is to provide a clear understanding of Cyclo Therapeutics' overall worth, which can help investors make informed investment decisions. There are several methods that can be used to perform Cyclo Therapeutics' net worth analysis. One common approach is to calculate Cyclo Therapeutics' market capitalization.Another approach is to use the price-to-earnings ratio (P/E ratio), which compares Cyclo Therapeutics' stock price to its earnings per share (EPS). Discounted cash flow (DCF) analysis is another popular method for assessing Cyclo Therapeutics' net worth. This approach calculates the present value of Cyclo Therapeutics' future cash flows, taking into account factors such as growth rate, profitability, and risk. By comparing the present value of Cyclo Therapeutics' cash flows to its current stock price, investors can gain a better understanding of the company's overall value. Finally, investors may use comparable company analysis to evaluate Cyclo Therapeutics' net worth. This involves comparing Cyclo Therapeutics' financial metrics to similar companies in the same industry. By identifying companies with similar financial characteristics, investors can gain insight into Cyclo Therapeutics' net worth relative to its peers.
Enterprise Value |
|
To determine if Cyclo Therapeutics is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Cyclo Therapeutics' net worth research are outlined below:
| Cyclo Therapeutics is way too risky over 90 days horizon | |
| Cyclo Therapeutics has some characteristics of a very speculative penny stock | |
| Cyclo Therapeutics appears to be risky and price may revert if volatility continues | |
| Cyclo Therapeutics has accumulated 1.03 M in total debt. Cyclo Therapeutics has a current ratio of 0.85, indicating that it has a negative working capital and may not be able to pay financial obligations in time and when they become due. Note, when we think about Cyclo Therapeutics' use of debt, we should always consider it together with its cash and equity. | |
| The entity reported the revenue of 1.08 M. Net Loss for the year was (20.06 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Cyclo Therapeutics has accumulated about 2.24 M in cash with (16.19 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.32, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Cyclo Therapeutics has a frail financial position based on the latest SEC disclosures | |
| Latest headline from news.google.com: Cyclo Therapeutics Completes Phase 3 Trial Enrollment, Plans 2025 NDA Filing Amid Merger CYTH Stock News - StockTitan |
Follow Cyclo Therapeutics' market capitalization trends
The company currently falls under 'Micro-Cap' category with a current market capitalization of 62.76 M.Market Cap |
|
Project Cyclo Therapeutics' profitablity
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (1.51) | (1.44) | |
| Return On Capital Employed | (4.20) | (4.40) | |
| Return On Assets | (1.51) | (1.44) | |
| Return On Equity | (4.22) | (4.43) |
When accessing Cyclo Therapeutics' net worth, it's important to look at multiple sources and consider different scenarios. For example, gross profit margin measures Cyclo Therapeutics' profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Cyclo Therapeutics' profitability and make more informed investment decisions.
Please note, the imprecision that can be found in Cyclo Therapeutics' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Cyclo Therapeutics. Check Cyclo Therapeutics' Beneish M Score to see the likelihood of Cyclo Therapeutics' management manipulating its earnings.
Evaluate Cyclo Therapeutics' management efficiency
Cyclo Therapeutics has return on total asset (ROA) of (2.8249) % which means that it has lost $2.8249 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (226.6391) %, meaning that it generated substantial loss on money invested by shareholders. Cyclo Therapeutics' management efficiency ratios could be used to measure how well Cyclo Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to climb to -1.44 in 2024. Return On Capital Employed is likely to drop to -4.4 in 2024. At this time, Cyclo Therapeutics' Total Assets are fairly stable compared to the past year. Other Current Assets is likely to climb to about 2.8 M in 2024, whereas Non Currrent Assets Other are likely to drop slightly above 36.4 K in 2024.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 0.29 | 0.28 | |
| Tangible Book Value Per Share | 0.29 | 0.28 | |
| Enterprise Value Over EBITDA | (0.89) | (0.93) | |
| Price Book Value Ratio | 5.46 | 7.66 | |
| Enterprise Value Multiple | (0.89) | (0.93) | |
| Price Fair Value | 5.46 | 7.66 | |
| Enterprise Value | 17.8 M | 18.6 M |
Examining the leadership quality of Cyclo Therapeutics offers valuable insights into its operational efficiency and financial health. This analysis assists investors in making informed decisions regarding the stock.
Revenue 1.1 M | Quarterly Revenue Growth 0.051 | Revenue Per Share 0.046 | Return On Equity (226.64) |
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Cyclo Therapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Cyclo Therapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Cyclo Therapeutics insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Toig Randall M. over a week ago Acquisition by Toig Randall M. of 3350 shares of Cyclo Therapeutics at 1.28 subject to Rule 16b-3 | ||
Wong Vivien over a month ago Disposition of tradable shares by Wong Vivien of Cyclo Therapeutics subject to Rule 16b-3 | ||
Strattan Ce Rick over two months ago Acquisition by Strattan Ce Rick of 8209 shares of Cyclo Therapeutics subject to Rule 16b-3 | ||
Ostronic Francis Patrick over six months ago Acquisition by Ostronic Francis Patrick of 3350 shares of Cyclo Therapeutics at 1.28 subject to Rule 16b-3 | ||
Joshua Fine over six months ago Acquisition by Joshua Fine of 41036 shares of Cyclo Therapeutics at 1.28 subject to Rule 16b-3 | ||
Shanahan William S over six months ago Acquisition by Shanahan William S of 25971 shares of Cyclo Therapeutics subject to Rule 16b-3 |
Cyclo Therapeutics Earnings per Share Projection vs Actual
Cyclo Therapeutics Corporate Management
| Michael Lisjak | Global Development | Profile | |
| George Fails | Ex Mang | Profile | |
| Jeffrey Tate | Chief COO | Profile | |
| Scott Fine | CEO Director | Profile | |
| Lori McKenna | Global Advocacy | Profile |
Additional Tools for Cyclo Stock Analysis
When running Cyclo Therapeutics' price analysis, check to measure Cyclo Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Cyclo Therapeutics is operating at the current time. Most of Cyclo Therapeutics' value examination focuses on studying past and present price action to predict the probability of Cyclo Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Cyclo Therapeutics' price. Additionally, you may evaluate how the addition of Cyclo Therapeutics to your portfolios can decrease your overall portfolio volatility.